Comparing Orchard Therapeutics (ORTX) and Its Competitors
Orchard Therapeutics (NASDAQ: ORTX) is one of 114 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Orchard Therapeutics to similar companies based on the strength of its analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.
Institutional and Insider Ownership
56.7% of Orchard Therapeutics shares are owned by institutional investors. Comparatively, 48.4% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 16.4% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This table compares Orchard Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Orchard Therapeutics Competitors||-5,144.22%||-64.24%||-27.96%|
Valuation & Earnings
This table compares Orchard Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Orchard Therapeutics||$2.08 million||-$230.49 million||-1.74|
|Orchard Therapeutics Competitors||$897.64 million||$190.37 million||-1.26|
Orchard Therapeutics’ rivals have higher revenue and earnings than Orchard Therapeutics. Orchard Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations and price targets for Orchard Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Orchard Therapeutics Competitors||837||2781||6069||261||2.58|
Orchard Therapeutics presently has a consensus target price of $24.50, indicating a potential upside of 37.72%. As a group, “Biological products, except diagnostic” companies have a potential upside of 39.88%. Given Orchard Therapeutics’ rivals higher possible upside, analysts plainly believe Orchard Therapeutics has less favorable growth aspects than its rivals.
Orchard Therapeutics Company Profile
Orchard Therapeutics plc, integrated biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Ltd. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Orchard Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchard Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.